INC. (NASDAQ:INCR) Files An 8-K Unregistered Sales of Equity Securities
Item 3.02 Unregistered Sales of Equity Securities.
As previously reported, SunHydrogen, Inc. (the “Company”) issued convertible notes to accredited investors which are convertible into shares of the Company’s common stock on the terms and conditions set forth in the various notes. On March 8, 2021, the Company issued 157,622,696 shares of common stock upon conversion of outstanding principal and accrued interest on a convertible note.
In connection with the foregoing, the Company relied upon the exemption from registration provided under Section 4(a)(2) of the Securities Act of 1933, as amended, for transactions not involving a public offering.
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
On March 9, 2021, the Company adopted an amendment to the Company’s bylaws to provide for the number of directors of the Company to be set by resolution of the board of directors.
Item 9.01 Financial Statements and Exhibits.
| 3.1 | Amendment to Bylaws |
SUNHYDROGEN, INC. Exhibit
EX-3.1 2 ea137578-ex31_sunhydrogen.htm AMENDMENT TO BYLAWS Exhibit 3.1 March 9,…
To view the full exhibit click here
About INC. (NASDAQ:INCR)
INC Research Holdings, Inc. is a global contract research organization (CRO). The Company is focused on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company operates through two segments: Clinical Development Services and Phase I Services. The Company’s Clinical Development Services segment offers all clinical development services, including full-service global studies, as well as ancillary services, such as clinical monitoring, investigator recruitment, patient recruitment, data management, study reports to assist customers with their drug development process, quality assurance audits and specialized consulting services. The Company’s Phase I Services segment focuses on clinical development services for Phase I trials, which include scientific exploratory medicine, first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds.
